My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
G1 Therapeutics Inc (GTHX)
GTHX nasdaq
United States
G1 Therapeutics

G1 Therapeutics Stock Analysis & Ratings

G1 Therapeutics Stock Analysis Overview

Smart Score
Learn more about TipRanks Smart Score
The G1 Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart


GTHX Stock Stats

Previous Close$12.65
Bid0 x 0
Ask0 x 0
Today’s Range$12.66 - $13.3
52-Week Range$10.81 - $37.07
Average Volume1.03M
Market Cap$540.79M
P/E Ratio-5.0
Earnings DateNov 10, 2021

Company Description

G1 Therapeutics Inc

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
John E. Bailey
700 Park Offices Drive, Research Triangle Park, NC, 27709, US


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


What was G1 Therapeutics’s price range in the past 12 months?
G1 Therapeutics lowest stock price was $10.81 and its highest was $37.07 in the past 12 months.
    What is G1 Therapeutics’s market cap?
    G1 Therapeutics’s market cap is $540.79M.
      What is G1 Therapeutics’s price target?
      The average price target for G1 Therapeutics is $48.20. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $78.00 ,the lowest forecast is $20.00. The average price target represents 277.45% Increase from the current price of $12.77.
        What do analysts say about G1 Therapeutics?
        G1 Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
          When is G1 Therapeutics’s upcoming earnings report date?
          G1 Therapeutics’s upcoming earnings report date is Nov 10, 2021 which is in 24 days.
            How were G1 Therapeutics’s earnings last quarter?
            G1 Therapeutics released its earnings results on Aug 04, 2021. The company reported -$0.936 earnings per share for the quarter, beating the consensus estimate of -$0.976 by $0.04.
              Is G1 Therapeutics overvalued?
              According to Wall Street analysts G1 Therapeutics’s price is currently Undervalued.
                Does G1 Therapeutics pay dividends?
                G1 Therapeutics does not currently pay dividends.
                What is G1 Therapeutics’s EPS estimate?
                G1 Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does G1 Therapeutics have?
                G1 Therapeutics has 42,350,000 shares outstanding.
                  What happened to G1 Therapeutics’s price movement after its last earnings report?
                  G1 Therapeutics reported an EPS of -$0.936 in its last earnings report, beating expectations of -$0.976. Following the earnings report the stock price went down -3.924%.
                    Which hedge fund is a major shareholder of G1 Therapeutics?
                    Among the largest hedge funds holding G1 Therapeutics’s share is Fisher Asset Management LLC. It holds G1 Therapeutics’s shares valued at 20M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis